Abstract
PPARγ has emerged as a key regulator of cell growth and survival, whose activity is modulated by a number of synthetic and natural ligands. Here we shall review the activities of PPARγ ligands in the control of immune cell proliferation, differentiation and apoptosis and their potential therapeutic applications to hematological malignancies.
Keywords: PPARγ ligands, cancer, immune system, cell cycle, apoptosis, TZDs, myeloid neoplasms, lymphoid neoplasms
Mini-Reviews in Medicinal Chemistry
Title: The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Volume: 7 Issue: 9
Author(s): C. Ulivieri and C. T. Baldari
Affiliation:
Keywords: PPARγ ligands, cancer, immune system, cell cycle, apoptosis, TZDs, myeloid neoplasms, lymphoid neoplasms
Abstract: PPARγ has emerged as a key regulator of cell growth and survival, whose activity is modulated by a number of synthetic and natural ligands. Here we shall review the activities of PPARγ ligands in the control of immune cell proliferation, differentiation and apoptosis and their potential therapeutic applications to hematological malignancies.
Export Options
About this article
Cite this article as:
Ulivieri C. and Baldari T. C., The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies, Mini-Reviews in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/138955707781662618
DOI https://dx.doi.org/10.2174/138955707781662618 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity
Mini-Reviews in Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)
Current Cancer Drug Targets Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry